The upregulation of CRP is associated with a poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy (40) and may indicate immunochemotherapy-related interstitial lung disease in B-cell lymphoma (41). Here, CRP is linked to B-cell non-Hodgkin lymphoma.